News and Trends 14 Sep 2022 Pancreatic cancer study using dual-cell therapy yields positive results Australian biotech company Noxopharm Limited has revealed encouraging new preclinical data from its long-term collaboration with UNSW Sydney. The results were reported this week at the American Association of Cancer Research (AACR) Special Conference on Pancreatic Cancer in Boston. The study involves Noxopharm’s novel preclinical drug, which attacks pancreatic cancer in a different and innovative […] September 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 14 Sep 2022 Rivaling the Golden Triangle at Bristol’s Science Creates hub The Golden Triangle region hosts much of the U.K.’s biotech innovation. However, there are many hubs emerging across the nation, with Bristol’s Science Creates network being one thriving example. The U.K. hosts one of Europe’s leading biotech industries in terms of startup formation, scientific publications and investments. “The U.K. punches well above its weight with […] September 14, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 Tumors destroyed in five types of cancer by cell therapy from LIfT BioSciences LIfT BioSciences announced today (September 14) that its cell therapy has shown tumor destruction across five different solid tumor types in tumoroid models. The N-LIfT cell therapy destroyed on average more than 90% of the tumoroid in a PDX organoid across five of the most challenging to treat solid tumor types. A PDX organoid is […] September 14, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2022 Results of phase 3 trial of injection for ovarian cancer imaging published An injection for intraoperative imaging of folate receptor positive ovarian cancer can identify more of the disease than is unable to be identified conventionally. Biotech company On Target Laboratories announced that the results from its phase 3, 006 study of the Cytalux (pafolacianine) injection had been published in the Journal of Clinical Oncology yesterday (September […] September 13, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2022 New predictive biomarkers to be developed for larynx and hypopharynx carcinomas A study to develop new, potential precision therapies in larynx and hypopharynx carcinomas has been announced today (September 13) by One Biosciences. The company was co-founded by Céline Vallot, Institut Curie and Home Biosciences, combining artificial intelligence (AI) and single-cell technologies to discover new therapeutic targets and develop novel precision medicines. The LARYCARE study, for […] September 13, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2022 Starpharma announces new data for prostate cancer trial Cabazitaxel (Jevtana, Sanofi) is a chemotherapy for the treatment of advanced prostate cancer (mCRPC). Developed by Australian biotech company Starpharma, DEP cabazitaxel is a patented, highly water soluble dendrimer nanoparticle version of standard cabazitaxel that has shown, in preclinical and clinical studies, benefits in terms of safety and efficacy. In a poster presentation at ESMO […] September 13, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2022 Himalaya Therapeutics publishes data on cancer treatment Himalaya Therapeutics has given an interim topline data update from its phase 2 study of HTBA3011 (mecbotamab vedotin) in non-small cell lung cancer (NSCLC) and certain sarcomas. In August, Himalaya’s collaboration partner, BioAtla publicly announced operational updates on the ongoing global clinical trials for HTBA3011 in patients with AXL-positive NSCLC who have previously failed PD-1/L1, […] September 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 PDC*line Pharma presents results from phase I/II trial PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, has revealed the first results of its PDC-LUNG-101 phase I/II clinical trial with PDC*lung01. PDC*lung01 is the company’s therapeutic off-the shelf cancer vaccine candidate for non-small cell lung cancer (NSCLC). The preliminary data was presented at […] September 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 Enterome presents more data on therapeutic cancer treatment Clinical stage biopharma company Enterome has presented new data from its two phase 1/2 clinical trials of its OncoMimics cancer immunotherapy EO2401. The trails are in combination with nivolumab (Opdivo) +/- bevacizumab (Avastin), in patients with first progression/recurrence of glioblastoma (ROSALIE trial), and in combination with nivolumab in patients with non-resectable adrenocortical carcinomas (ACC) and […] September 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 Astellas, Seagen and Merck give details on urothelial cancer treatment Astellas Pharma Inc., Seagen Inc. and Merck (known as MSD outside of the U.S. and Canada), have announced results from the phase 1b/2 EV-103 clinical trial (KEYNOTE-869) Cohort K investigating PADCEV (enfortumab vedotin-ejfv) in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) and PADCEV alone as first-line treatment in patients with unresectable locally advanced or metastatic […] September 12, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 Ayala Pharmaceuticals presents interim data on desmoid tumor trial Clinical oncology company Ayala Pharmaceuticals, Inc. has announced updated, positive interim results from part A of its ongoing RINGSIDE pivotal phase 2/3 clinical trial evaluating investigational new drug AL102 in desmoid tumors. Ayala Pharmaceutical’s AL102 is a selective, oral gamma-secretase inhibitor. The data are being featured in an oral presentation at the European Society for […] September 12, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 Reveal Genomics reveals more HER2DX breast cancer validation data Reveal Genomics, S.L. says it has received more validation of HER2DX, the world’s first specialized genomic test for HER2+ breast cancer. Valentina Guarneri from the University of Padova presented the data at the European Society of Medical Oncology Congress 2022 in Paris, France. The data obtained from the analysis of tumor samples from the PerELISA […] September 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email